Fig. 4: MTS105 effectively eradicates GPC3+ xenograft tumors in humanized mice. | Nature Communications

Fig. 4: MTS105 effectively eradicates GPC3+ xenograft tumors in humanized mice.

From: Organ-specific delivery of an mRNA-encoded bispecific T cell engager targeting glypican-3 in hepatocellular carcinoma

Fig. 4

A Treatment schedule of the in vivo efficacy study. Effect of MTS105 in NOG mice engrafted with human PBMCs and bearing mouse Hep3B-luc tumors. After grouping, mice were treated with MTS105 (0.5 and 0.1 μg/mouse), ERY974 (0.3 mg/kg), LNP empty (0.5 μg/mouse), or Tris vehicle. B Tumor growth was monitored by means of bioluminescence imaging. n = 6 mice per group. C Tumor growth for individual mice. D MTS105-encoded TCE concentration was quantified by ELISA in serum from orthotopic HCC mice at 6 h after the first treatment (n = 6 biologically independent samples). Data are expressed as mean ± SD. A one-way ANOVA was used to compare groups. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Back to article page